EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation

BACKGROUND: Sunitinib is one of the multi-targeted tyrosine kinase inhibitors for the treatment of renal cell carcinoma (RCC) at present. However, its clinical efficacy is limited by chemoresistance of RCC. Our previous study found that eukaryotic translation initiation factor 3 subunit D (EIF3D) wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hai, Gao, Yi, Liu, Ao, Yang, Xiaoqun, Huang, Fang, Xu, Le, Danfeng, Xu, Chen, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945244/
https://www.ncbi.nlm.nih.gov/pubmed/31669222
http://dx.doi.org/10.1016/j.ebiom.2019.10.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945244/
https://www.ncbi.nlm.nih.gov/pubmed/31669222
http://dx.doi.org/10.1016/j.ebiom.2019.10.030

Ejemplares similares